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Abstract
Iron is an essential nutrient that facilitates cell proliferation and growth. However, iron also has
the capacity to engage in redox cycling and free radical formation. Therefore, iron can contribute
to both tumour initiation and tumour growth; recent work has also shown that iron has a role in the
tumour microenvironment and in metastasis. Pathways of iron acquisition, efflux, storage and
regulation are all perturbed in cancer, suggesting that reprogramming of iron metabolism is a
central aspect of tumour cell survival. Signalling through hypoxia-inducible factor (HIF) and
WNT pathways may contribute to altered iron metabolism in cancer. Targeting iron metabolic
pathways may provide new tools for cancer prognosis and therapy.
Elemental iron has crucial functions in mammalian cells. Iron enables the function of vital
iron- and haem-containing enzymes, including mitochondrial enzymes that are involved in
respiratory complexes, enzymes involved in DNA synthesis and the cell cycle, detoxifying
enzymes such as peroxidase and catalase, and many more1. Therefore, iron is essential for
cell replication, metabolism and growth. However, the ability to gain and lose electrons —
the very attribute that makes iron useful enzymatically — also enables iron to participate in
potentially deleterious free radical-generating reactions. Among these is the Fenton reaction,
in which ferrous iron donates an electron in a reaction with hydrogen peroxide to produce
the hydroxyl radical, a reactive oxygen species (ROS). This reaction not only damages lipids
and proteins, but also causes oxidative damage to DNA, including DNA base modifications
and DNA strand breaks2,3, which can be mutagenic4. Therefore, iron is both essential and
potentially toxic.
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Both the beneficial and deleterious effects of iron have a role in cancer. For example, iron
may accelerate tumour initiation by enhancing the formation of free radicals, as well as
function as a nutrient that fosters tumour cell proliferation. The extent to which and the
mechanisms by which iron has such roles have been debated for decades. As early as 1940,
exposure to iron oxide dust was shown to triple the incidence of pulmonary tumours in
mice5; in the 1950s, intramuscular injection of iron–dextran was shown to induce sarcoma in
rats6. In the 1990s, it was demonstrated that the growth rate of tumour xenografts could be
influenced by levels of dietary iron7,8. Many years and experiments later, a clearer picture
linking excess iron and altered iron metabolism to cancer is emerging, based on evidence
ranging from epidemiological to molecular (TABLE 1).
Unravelling the complex relationship between iron and cancer has been facilitated by the
recent discovery of new proteins that participate in and control iron metabolism. For
example, newly identified iron efflux pumps, systemic iron regulators, oxidases and
reductases that maintain iron in the appropriate valence state, as well as siderophore-binding
proteins, are providing resolution to the picture of how tumour cells reprogramme iron
metabolism. Studying the role of iron and cancer has also revealed that proteins involved in
iron metabolism may be multifunctional and can contribute to malignancy in ways that are
independent of their primary role in iron metabolism. Recent studies not only provide
insights into cellular and systemic iron metabolism that explain and redefine the
relationships between iron and cancer, but may also provide new tools for cancer therapy
and for determining prognosis.
Clinical and population-based studies
Population-based studies have taken four general approaches to examine the relationship
between iron and cancer risk. Although the results are not always consistent, these studies
collectively support a model in which increased levels of iron in the body are associated
with increased cancer risk. An overview of mechanisms that regulate the content of body
iron in humans and its metabolism in cells is described below (FIGS 1,2). Following uptake
from the diet, iron is loaded onto transferrin (TF), which can bind two atoms of ferric (Fe3+)
iron. TF-bound iron circulates in the bloodstream and delivers iron to peripheral tissues by
binding to transferrin receptor 1 (TFR1), which is a broadly expressed cell surface receptor.
The diferric iron–TF–TFR1 complex is endocytosed; in the acidic environment of the
endosome, and with the assistance of STEAP reductases, ferric iron is reduced to ferrous
iron (Fe2+). Divalent metal transporter 1 (DMT1; also known as NRAMP2) then facilitates
the egress of ferrous iron from the endosome into a pool of loosely bound iron, which is
termed the labile iron pool. From this pool, iron is delivered to multiple intracellular
destinations. It is incorporated into the active site of proteins such as ribonucleotide
reductase, where it participates in the catalytic conversion of ribonucleotides to
deoxyribonucleotides; iron is also used in the synthesis of haem and iron–sulphur clusters,
which are in turn incorporated into proteins that carry out the citric acid cycle, oxidative
phosphorylation and many other essential functions. Excess iron, which exceeds the levels
required for the synthesis of these proteins, is stored in the iron storage protein ferritin. Iron
can also be exported from cells through ferroportin (also known as SLC40A1), which is an
iron efflux pump. This process involves oxidases such as ceruloplasmin or hephaestin,
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which oxidize iron back to the ferric form before loading onto TF. Levels of ferroportin are
partly regulated by the circulating peptide hormone hepcidin, which binds to ferroportin and
triggers its degradation.
In an early study examining the association between biochemical markers of iron stores and
cancer, Stevens and co-workers analysed more than 14,000 participants in the first US
National Health and Nutrition Examination Survey (NHANES)9,10. They demonstrated that
saturation of the iron-binding transporter TF at study enrolment was significantly higher in
men who subsequently developed cancer than in those who did not develop cancer.
Subsequent studies revealed similar trends11–13. However, analysis did not include other
measures that are thought to more closely mirror levels of iron in the body, such as serum
levels of ferritin, which is a limitation of these studies.
A second analytical approach has explored the association between dietary iron intake and
cancer risk. A meta-analysis of 33 studies assessing iron intake and colorectal cancer
revealed that approximately three-quarters of these studies associated higher iron intake with
an increased risk of colorectal cancer14. A less consistent association between iron
consumed either in the diet or as a supplement and an increased risk of developing other
types of cancer has also been observed (for example, see REFS 15,16). Variable results can
be partly attributed to inherent difficulties in conducting these studies, such as inferential
assessments of iron intake, variability in iron absorption post-intake, assessment of iron
intake at a single point in time as a surrogate for long-term exposure and sample size. Recent
studies suggest that the dietary source of iron (haem versus non-haem) and genetic
polymorphisms in antioxidant enzymes may further complicate these studies17–20.
A third approach has been to use genetically induced accumulation of excess iron (known as
iron overload) to infer the consequences on cancer. Hereditary haemochromatosis is a
genetic disorder that is characterized by iron overload, particularly in the parenchymal cells
of the liver, heart and endocrine organs (reviewed in REF. 21). Liver cirrhosis with
hepatocellular carcinoma accounts for approximately 20–30% of deaths in untreated or
poorly treated patients with hereditary haemochromatosis22,23, which is a 20–200-fold
increased risk for these patients22,24,25. Subjects that carry mutations in haemochromatosis
(HFE), one of the mutated genes that underlies hereditary haemochromatosis, may also be at
an increased risk of extrahepatic cancer, including breast, colorectal and other cancers26,27.
The effect of a clinically driven reduction in body iron stores on cancer risk is the fourth
epidemio logical link between iron and cancer. Thus, repeated phlebotomy over
approximately 4.5 years in elderly men with peripheral artery diseases reduced the overall
cancer risk (hazard ratio (HR) 0.65; P = 0.036) and cancer-specific mortality (HR 0.49; P =
0.009). Although the authors interpreted their results cautiously, this is consistent with other
observations of a decreased risk of several cancers (such as liver, lung, colon, stomach and
oesophageal cancer) in individuals who frequently donate blood28.
Intracellular iron regulation is modified in cancer
The past decade, which has been marked by the discovery of new iron-associated proteins
and pathways, has been described as a ‘golden age’ of iron metabolism29 (FIG. 2). This
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decade has reaped the rewards of these discoveries by applying them to deciphering
molecular relationships between iron and cancer. Many proteins that were originally studied
for their roles in normal iron metabolism have now been shown to contribute to malignant
growth. It seems that cancer cells retain most elements of the general iron metabolism
pathway, although for many cancer types this has not been rigorously or explicitly studied.
However, cancer cells differ from their non-malignant counterparts in the levels or activity
of many of the proteins that are involved in iron metabolism. In many cases, the net result of
these cancer-specific alterations is an increase in intra cellular iron levels that fuels the
activity of iron-dependent proteins and enables enhanced proliferation. In some cases, the
downstream consequences of changes in iron-regulated proteins remain unclear.
The regulation of iron uptake in cancer
FIGURE 3 depicts some crucial changes in iron uptake and efflux that have been identified
in malignant cells. TFR1 is highly expressed in many cancers, including breast cancer,
leukaemia, lymphoma, bladder cancer, lung cancer, glioma and others30. Consequently,
TFR1 antibodies have been used to inhibit tumour growth31,32; toxic moieties conjugated to
its ligand (TF) have also been widely used for the tumour-selective delivery of anticancer
agents30. Some members of the STEAP family of metalloreductases (which participate in
iron uptake by reducing endosomal ferric iron to ferrous iron)33 are also over-expressed in
cancer, including STEAP1, STEAP2 and STEAP3. However, because STEAP1 does not
possess reductase activity34, not all STEAP family members may be associated with cancer
through their effects on iron metabolism.
Lipocalin 2 (LCN2; also known as NGAL and 24p3) is a less well-studied protein that is
involved in an alternative pathway of iron uptake that is also upregulated in some cancers,
including breast35, liver36 and pancreatic cancer37. LCN2 binds siderophores, which are low
molecular mass iron-binding ligands that are best known for their roles in iron acquisition by
bacteria and fungi38. Mammalian cells synthesize catechol, which is an iron-binding
molecule with the properties of a siderophore, and iron circulates in the blood bound to an
LCN2–catechol complex39. This complex binds to the cell surface receptor 24p3R (also
known as SLC22A17) and can serve as a mechanism of iron delivery. By contrast,
internalization of unligated LCN2 can serve as a mechanism of iron efflux and can lead to
cell death40. Overexpression of LCN2 in MCF7 breast cancer cells increases proliferation41
and increases angiogenesis in a corneal pocket angiogenesis assay42. Conversely, inhibition
of LCN2 inhibits breast tumorigenesis in two different mouse models of cancer35,43,
although no correlation between LCN2 expression and breast tumour aggressiveness was
observed in a different genetic background44. In mouse models of colorectal cancer, LCN2
expression was associated with reduced metastasis45 although, paradoxically, it was also
associated with the decreased overall survival of patients with colorectal cancer46.
Nevertheless, recent results suggest that LCN2 expression is associated with shorter disease-
free survival47 and is an independent prognostic factor for decreased disease-free survival in
primary human breast cancer48; LCN2 is also associated with a poor prognosis in
hepatocellular carcinoma36.
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Regulation of iron storage in cancer
Most cells, including cancer cells, store excess intracellular iron in ferritin, where it can be
safely sequestered from participation in radical-generating reactions (FIG. 2). Ferritin is a
24-subunit protein that can store up to 4,500 iron atoms in a ferrihydrite mineral core. It is
composed of two subunit types, termed ferritin heavy chain (FTH) and ferritin light chain
(FTL) subunits. Ferritin is regulated by iron-regulatory protein 1 (IRP1; also known as
ACO1) and IRP2 (also known as IREB2), which post-transcriptionally repress ferritin
expression and increase TFR1 expression (discussed further below) (FIG. 4). Expression of
the proto-oncogene MYC in B cells induces IRP2 expression and represses ferritin
expression49. It has been suggested that the consequent reduction in iron storage and
increase in TFR1 (a downstream effect of IRP2 activation) could increase the intracellular
availability of iron for metabolic and proliferative purposes. A direct effect of MYC on
TFR1 and DMT1 expression was subsequently demonstrated in colon cancer50. The E1a
oncogene found in adenovirus similarly represses ferritin51. Studies on cells expressing the
HRAS oncogene revealed that the downregulation of ferritin increases the labile iron pool
and stimulates proliferation52,53, demonstrating that oncogene-induced changes in the iron
storage protein ferritin are sufficient to increase the labile iron pool and increase
proliferation. The tumour suppressor p53 may exert the opposite effect: p53 induces ferritin
by inactivating IRPs54,55, which was suggested to contribute to p53-mediated growth arrest
by restricting the availability of iron54. Downregulation of ferritin increases the sensitivity
of breast cancer cells to the chemotherapeutic agents doxorubicin56 and carmustine57,
presumably by increasing intracellular oxidative stress.
Ferritin is also intimately connected to nuclear factor-κB (NF-κB) signalling. NF-κB is a
widely expressed transcription factor that is involved in many processes, including
inflammation and cancer58. FTH1 is transcriptionally induced by tumour necrosis factor
(TNF)59, an effect that is mediated through NF-κB in fibroblasts60. An increase in the
ferritin protein (through the induction of FTH1 expression) has a key role in NF-κB-
mediated survival signalling: by sequestering iron, ferritin thereby prevents oxidative stress
and proapoptotic JUN N-terminal kinase (JNK) signalling, which is activated by oxidative
stress61. Functioning upstream of the pathway, extracellular ferritin may also induce NF-κB
signalling in hepatic stellate cells62. It is intriguing that the connection between NF-κB and
ferritin has not generally been made in cancer cells themselves, but has been made in
fibroblasts and inflammatory cells that may model the tumour microenvironment. Thus, both
the downregulation and the upregulation of ferritin63 may contribute to tumour survival in
the appropriate cellular context: ferritin upregulation may support the survival of
inflammatory and stromal cells in the microenvironment, whereas ferritin down-regulation
may increase the metabolic availability of iron in the cancer cells themselves, albeit at the
cost of persistent oxidative stress64.
The regulation of iron efflux in cancer
Cancer cells increase metabolically available iron not only by increasing iron uptake and
decreasing iron storage, but also by decreasing iron efflux. One of the most important recent
discoveries in iron biology has been the identification of the ferroportin–hepcidin regulatory
axis65. These two proteins, which substantially contribute to the regulation of systemic iron
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levels, also have a key role in cancer. Ferroportin is the only known iron efflux pump in
vertebrates. Its expression on the cell surface of enterocytes is regulated by the circulating
peptide hormone hepcidin. When intracellular storage and circulating levels of iron are high,
hepcidin is induced in hepatocytes via a bone morphogenetic protein (BMP)-mediated
pathway and is secreted into the circulation66. Hepcidin binds to ferroportin on the
basolateral side of enterocytes and triggers ferroportin internalization into clathrin-coated
pits and its subsequent lysosomal degradation67, thus blocking the delivery of iron from the
digestive tract to the blood. Simultaneously, hepcidin binds to ferroportin on macrophages
and blocks iron recycling, which further limits iron availability (FIG. 1). Mutations in the
ferroportin–hepcidin axis that disrupt this pathway lead to inappropriate iron accumulation
and hereditary haemochromatosis21.
Ferroportin is expressed not only in tissues that are important for the regulation of systemic
iron homeostasis, but also in breast tissue68,69. Somewhat surprisingly, hepcidin is also
expressed in breast epithelial cells69, thus creating the potential for a local autocrine and/or
paracrine iron-regulatory loop. Ferroportin is down-regulated in breast cancer cell lines70
and in human breast cancer samples69. Decreased ferroportin levels were associated with
increased levels of the labile iron pool in cultured breast cancer cells and with the increased
growth of breast tumour xenografts69. Decreased ferroportin expression was significantly
associated with a poor prognosis in four separate cohorts comprising approximately 800
patients with breast cancer69. Further, when all patients were combined, in women whose
tumours expressed high levels of ferroportin, concomitant expression of high levels of
hepcidin reduced distant metastasis-free survival. Interrogation of gene expression in a
homogeneously treated subpopulation of 276 oestrogen receptor-positive (ER+) tamoxifen-
treated patients demonstrated that the combination of high ferroportin and low hepcidin was
associated with a favourable prognosis, even in women with lymph node metastases. This
suggests that the measurement of ferroportin and hepcidin levels in breast tumours could be
used in breast cancer prognosis. Furthermore, because the end point of these analyses was
the presence of metastasis, these studies indirectly suggest that ferroportin levels are
important not only in the growth of primary tumours, but also in metastatic spread.
Subsequent work revealed the association of additional ‘iron genes’ with breast cancer
prognosis71. Sixty-one genes with functions related to iron metabolism were selected and
analysed for their association with the survival of patients with breast cancer71. The
expression of 49% of these genes was significantly associated with distant metastasis-free
survival, a much larger proportion than would be expected by chance (P <0.02). Most of the
prognostic information contained in these genes could be captured using 16 of the 61 genes;
this 16 gene set was termed the iron-regulatory gene signature (IRGS), and could be
successfully used to discriminate among patients with breast cancer who had a high, a
medium or a low risk of distant metastasis-free survival. This included lymph node-positive
tamoxifen-treated patients, who are generally considered a high-risk group; assessment of
the IRGS in these patients may spare some of these women unneeded chemotherapy.
Several gene signatures are likely to be embedded in the IRGS71. For example, the
expression of two separate gene dyads was particularly important in determining patient
outcome: TFR1 (also known as TFRC) and HFE, which control iron import; and ferroportin
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and hepcidin, which control iron export71. These two dyads seem to represent alternative
pathways that lead to the same outcome: tumours with a low iron uptake profile
(TFR1lowHFEhi) did not frequently overlap with those that expressed a high iron efflux
profile (ferroportinhihepcidinlow), but both conferred a favourable prognosis71. These results
suggest that the expression of multiple iron pathways affects the prognosis of patients with
breast cancer.
In addition to the effects of hepcidin that is synthesized by tumours, systemic hepcidin that
is synthesized by the liver contributes to cancer in other ways. Many cancer patients suffer
from anaemia of chronic disease, a syndrome that is characterized by iron deregulation and
anaemia72. It has been argued that the systemic lack of iron availability that is characteristic
of this syndrome, which is sometimes referred to as the iron withholding response, is a host
response that combats cancer by depriving tumours of iron73,74. Whatever its teleological
explanation, anaemia of chronic disease is linked to the upregulation of hepcidin — which is
induced by BMP2 in myeloma75 and by interleukin-6 (IL-6) in Hodgkin’s lymphoma76.
Targeting this pathway may be of substantial clinical benefit in ameliorating this syndrome,
which is estimated to affect 40–70% of cancer patients72. However, the potential of the
ensuing increase in iron absorption to promote tumour growth will have to be considered
when designing such a strategy.
Iron-regulatory proteins
The conceptual link between cancer and proteins that regulate iron uptake or efflux is
straightforward, because levels of these proteins directly affect intracellular iron content.
How other proteins that are associated with iron regulation influence cancer is less certain;
for example, IRP1 and IRP2. These proteins are master regulators of intracellular iron
homeostasis that function to increase iron uptake when intracellular iron levels are low and
decrease cellular iron uptake when intracellular iron levels are high (FIG. 4). This is
accomplished by IRP-mediated translational regulation of the proteins that are associated
with iron import, storage and efflux. When iron is scarce, IRPs bind to iron-response
elements (IREs) in the 5′ untranslated region (UTR) of ferritin and ferroportin mRNAs,
which blocks their translation and consequently inhibits iron storage and efflux. At the same
time, IRPs also bind to IREs in the 3′ UTR of TFR1 mRNA, which stabilizes the mRNA
and increases iron import. A 3′ IRE is also present and contributes to iron-dependent
regulation of IRE-containing isoforms of the iron transporter DMT1, presumably through a
mechanism similar to that of TFR1 (REFS 77,78). Despite the apparently similar roles of
IRP1 and IRP2, overexpression of IRP1 reduces tumour growth in vivo, whereas
overexpression of IRP2 promotes tumour growth in vivo79,80. The reason for these opposing
phenotypes has not been explained, although it has been suggested that IRP2 may have
functions that are unrelated to its role in iron metabolism, such as the induction of MYC and
MAPK signalling79, which may account for its tumour-promoting effects.
Iron and the tumour microenvironment
Tumours exist in a rich microenvironment that includes endothelial cells and macrophages,
among other cell types81. M2-polarized macrophages, which resemble tumour-associated
macrophages, were recently shown to exhibit a gene expression profile that is consistent
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with iron efflux: an increase in ferroportin and a decrease in ferritin82. Conditioned media
from M2 macrophages promoted tumour cell proliferation, an effect that was inhibited by
iron chelation, suggesting that macrophages may foster tumour growth partly by providing
tumour cells with iron82,83. Ferritin, which is best known for its role in intracellular iron
storage, is also secreted by macrophages84. Independently of its role as a potential additional
iron source85,86, secreted ferritin may promote tumour angiogenesis by binding cleaved high
molecular weight kininogen (HMWK; also known as kininogen 1, the cleaved form of
HMWK is termed HKa), which is an endogenous angiogenesis inhibitor87,88.
The iron ‘metabolic switch’ and hypoxia
Frataxin is a mitochondrial protein that is implicated as a cause of the neurodegenerative
disorder Friedreich’s ataxia. Although cancer is not a hallmark of the disease, there are
several reports of cancer in young patients with Friedreich’s ataxia89,90. Frataxin has a
crucial role in the initial steps of iron–sulphur cluster biogenesis, possibly by serving as an
iron donor or as an allosteric regulator (reviewed in REF. 91). Frataxin dysfunction leads to
the accumulation of mitochondrial iron92, and the production of ROS and oxidative stress93.
Liver-specific knockout of frataxin impairs mitochondrial function and promotes the
development of liver tumours in mice94. Conversely, the overexpression of frataxin in
human colon cancer cell lines decreases their growth, colony formation in soft agar and
tumour growth in xenografts95. As overexpression of frataxin also increased oxidative
metabolism (as measured by increased mitochondrial membrane potential, cell respiration
and ATP content), it was speculated that frataxin may inhibit tumour formation by reversing
the metabolic switch to aerobic glycolysis (the Warburg effect), which occurs in many
cancer cells95. Whether frataxin indeed exerts its effects by modifying metabolism and/or by
other mechanisms, including the prevention of oxidative DNA damage and fostering DNA
repair96, has not yet been definitively addressed.
Iron levels can also regulate hypoxia-inducible factor-α (HIFα) proteins, transcription
factor sub units that are central to the regulation of the response to hypoxia (reviewed in
REF. 97). There are three HIFα family members: HIF1α, HIF2α and HIF3α. These
subunits form heterodimers with HIF1β (also known as ARNT) to form the HIF
transcription factors, which transcriptionally induce numerous genes that are important in
the response to hypoxia, including vascular endothelial growth factor A (VEGFA),
erythropoietin (EPO), glucose transporter 1 (GLUT1; also known as SLC2A1) and survivin
(also known as BIRC5). HIFα subunits are post-translationally regulated by prolyl
hydroxylases (PHD proteins), which are iron-, 2-oxoglutarate- and oxygen-dependent
enzymes that modify HIFα subunits, and this modification targets them for proteasomal
degradation. In conditions of normoxia, HIFα is degraded, but under conditions of hypoxia,
HIFα is stabilized. Because the PHD proteins require iron for their activity, the HIF
transcription factors are also stabilized (and become transcriptionally active) when
intracellular iron levels are low.
HIF activity is increased in many tumours98, and upregulation of HIFα is frequently
associated with tumour growth and progression97. The stabilization of HIFα in tumours at
first seems to be inconsistent with a view of tumour cells as iron-avid cells. However, two
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sets of observations may reconcile this apparent paradox. First, HIF can be activated by
hypoxia even under conditions of high iron levels99. Thus, HIF activation in a tumour
environment does not necessarily connote low iron levels. Second, once activated, HIF1
promotes iron uptake. In cell culture, HIF1 induces TFR1 expression, thus increasing iron
uptake100,101. HIF1 also induces the expression of haem oxygenase 1 (HO1)102, which
degrades haem into biliverdin, carbon monoxide and iron; this intracellular release of iron
by HO1 enables iron to be recycled. HIF1 also induces the expression of ceruloplasmin,
which oxidizes iron to facilitate the loading of iron onto TF103. In addition to modulating
cellular iron levels, HIF2 promotes systemic iron uptake by inducing the expression of
ferroportin, DMT1 and duodenal cytochrome b (DCYTB; also known as CYBRD1) in
enterocytes104–106. Thus, HIF activation may contribute to enhanced iron accumulation in
tumours. Supporting this view, activated HIF2 was recently shown to promote colorectal
cancer by inducing DMT1 expression and increasing iron uptake in Apcmin/+ mice107.
Iron regulates DNA metabolism and the cell cycle
The involvement of iron in processes related to DNA replication, maintaining genomic
integrity (including DNA repair) and epigenetic regulation contribute both to the tumour-
initiating and to the tumour-promoting propensities of iron (FIG. 5). Cells starved of iron
accumulate in the G1 phase of the cell cycle108, which is consistent with a crucial role for
iron in DNA synthesis. Ribonucleotide reductase catalyses the rate-limiting step in DNA
synthesis, the reductive conversion of ribonucleotides to deoxyribonucleotides. This enzyme
is essential for cell viability and is a target of the chemotherapeutic agenthydroxyurea. The
catalytic activity of ribonucleotide reductase is dependent on a dinuclear iron site in the M2
subunit of the enzyme ribonucleoside-diphosphate reductase subunit M2 (RRM2)109,110.
The dependence of ribonucleotide reductase activity on iron has motivated the search for
anticancer drugs that inhibit its activity through iron chelation; several of these are currently
being tested in preclinical and clinical studies111,112 (dis cussed below) (TABLE 2). More
recently, a p53-inducible RRM2 subunit (p53R2; also known as RRM2B) has been
discovered113, which is induced in response to DNA damage. p53R2 has a >100-fold
increased susceptibility to iron chelation114, possibly owing to a unique pore in the
immediate vicinity of the iron-binding site, as demonstrated by X-ray crystallography115.
Because p53R2 is less susceptible to inhibition by hydroxyurea than RRM2, but is sensitive
to iron chelation, it represents a target for iron chelation therapy in tumours with wild-type
p53.
The iron dependence of DNA synthesis may extend beyond RRM2. All four replicative
DNA polymerases in yeast were recently shown to contain an iron–sulphur cluster, [4Fe–
4S], which has an essential role in their function116. DNA synthesis thus directly depends on
components of iron–sulphur cluster biogenesis from mitochondria and the cytosol, which
may explain why mitochondrial dysfunction (and thus defective iron–sulphur cluster
biogenesis) leads to genome instability117. Defective iron–sulphur cluster biogenesis may
also contribute to genome instability by inhibiting the activity of iron–sulphur cluster-
dependent enzymes that are involved in DNA repair and recombination, including
Xeroderma pigmentosum group D-complementing protein (XPD; also known as ERCC2),
Fanconi anaemia group J protein (FANCJ)118, DNA replication helicase 2 homologue
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(DNA2)119 and regulator of telomere elongation helicase 1 (RTEL1)120,121. Consistent with
this concept, defects in the assembly of a subset of iron–sulphur cluster-containing proteins
augment the sensitivity of cells to DNA damage121. Additionally, TET1, a ferrous iron- and
2-oxoglutarate-dependent enzyme that is disrupted in some haematological malignancies122,
catalyses the conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian
DNA. 5-hydroxymethylcytosine is a modified DNA base that is implicated in the early
stages of carcinogenesis123. This suggests that epigenetic regulation may represent yet
another pathway through which iron can alter DNA function and induce malignant
change124.
Proteins that control the cell cycle are also regulated by iron levels (reviewed in REF. 125).
Cyclin D1 associates with cyclin-dependent kinase 4 (CDK4) and CDK6 to regulate G1/S
progression by phosphorylating RB, which in turn releases the transcription factor E2F from
RB. Work with chemically unrelated iron chelators in breast and kidney cancer cell lines
demonstrated that iron depletion reduces cyclin D1 expression by stimulating cyclin D1
proteasomal degradation126,127. Thus far, how iron deprivation promotes this degradation
pathway remains unknown.
Iron affects WNT signalling
Effects on signalling represent a fairly unexplored mechanism through which iron affects
tumour cell proliferation and growth. Although iron has been implicated in several
signalling pathways60–62,128–131, the link between iron and WNT signalling may be
particularly important in cancer (FIG. 6). Aberrant WNT signalling contributes to many
types of cancer (reviewed in REFS 132,133). WNT signalling culminates in the
accumulation of β-catenin, which activates the T cell factor (TCF)–lymphoid enhancer
factor (LEF) transcription factor complex that induces the expression of target genes such as
MYC. WNT signalling is regulated through a destruction complex composed of
adenomatous polyposis coli (APC), axin, casein kinase 1 (CK1) and glycogen synthase
kinase 3β (GSK3β), which actively targets β-catenin for degradation. Some β-catenin is
also sequestered from the destruction complex through an association with E-cadherin.
Because inactivating mutations in APC are an early event in colorectal cancer, and because
alterations in iron transport proteins have been observed in colorectal cancer tissue, the role
of iron in WNT signalling has been investigated134. It was found that iron has two important
effects: it augments WNT signalling in cells with aberrant APC or β-catenin, and it also
downregulates E-cadherin in an APC-independent manner. These effects of iron on WNT
signalling may provide a mechanistic explanation for how iron exacerbates intestinal
tumorigenesis, particularly in a background of APC mutation.
These cell culture observations were supported by recent experiments in Apcmin/+ mice50, a
mouse model of intestinal cancer in which APC is inactivated. High levels of dietary iron
accelerated tumour formation and low iron levels reduced tumour formation in this mouse
model. High dietary iron levels induced MYC, TFR1 and DMT1 expression in intestinal
polyps from Apcmin/+ mice, as well as human adenomas and carcinomas50. Intriguingly, the
stem cell compartment was particularly responsive to iron manipulation. Further, dietary
iron, but not systemic iron, was crucial to intestinal tumorigenesis: the reduction in tumour
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burden in mice fed a low-iron diet was not reversed by raising levels of circulating iron by
subcutaneous injection of iron–dextran. In addition, lowering levels of circulating iron
through the administration of an iron chelator did not provide the same protection as dietary
iron restriction. This suggests that dietary iron may be more effective than systemic iron in
modifying WNT signalling, at least in the intestinal epithelium, which is directly exposed to
dietary iron in a way that most tissues are not. Supporting the finding that dietary iron
increases cancer risk, iron-enriched diets have similarly been shown to increase colorectal
tumour incidence in a mouse model of colitis135; a high-iron diet also enhanced proliferation
and the formation of large adenomas in an azoxymethane-induced mouse model of colon
cancer136. Conversely, low-iron diets reduced the growth of colon cancer (as well as
mammary adenocarcinoma and hepatoma) xenografts in mice7.
Reinforcing the dependence of WNT signalling on iron, two independent groups identified
iron chelators as top hits in high-throughput screens for WNT inhibitors137,138. In one
study137, several acyl hydrazones were identified as inhibitors of WNT signalling that
function downstream of the destruction complex. A novel, structurally distinct iron chelator,
HQBA, was identified in another study as a potent inhibitor of WNT signalling138. HQBA
binds ferrous iron with high affinity (dissociation constant 1.2 × 10−19M) and inhibited the
growth of spontaneous mammary tumours in both mouse mammary tumour virus (MMTV)-
Wnt1 and MMTV-polyoma middle T (PyMT) mouse models. In line with these findings,
leukaemic blasts from seven of nine patients with acute myeloid leukaemia (AML) who
were treated in a Phase I trial with another chelator, ciclopirox, exhibited a time-dependent
decrease in the expression of AXIN2, a member of the WNT signalling pathway137.
Although the iron chelators identified by both groups function downstream of β-catenin to
inhibit WNT signalling, the precise target of these chelators remains to be determined.
Aberrant WNT signalling was also observed in an iron-induced mouse model of kidney
cancer. In a series of elegant experiments, ferric nitrilotriacetate (FeNTA), a soluble iron
salt, was shown to induce nephrotoxicity and kidney cancer in rats and mice139–142.
Nitrilotriacetate (NTA) itself was non-carcinogenic, implicating iron as the causative agent
in this compound141. Direct analysis of chromatin from the kidneys of rats treated with
FeNTA revealed the presence of 8-hydroxy-2′-deoxyguanosine (8-OH-dG) and other
modified DNA bases that are hallmarks of oxidatively damaged DNA142. When the
mutation range induced by FeNTA in vivo was evaluated, transversions, substitutions and
deletions were identified, as well as the loss of CDK inhibitor 2A (Cdkn2a; which encodes
the tumour suppressors ARF and INK4A)143,144. High-resolution microarray comparative
genomic hybridization of renal tumours that were induced by FeNTA in rats revealed
extensive genomic alterations, including amplifications and deletions, with Met
amplification and Cdkn2a and Cdkn2b deletion being the most common alterations145. The
global pattern of genetic alterations closely paralleled those seen in human renal
carcinoma145. FeNTA-induced tumours demonstrated a 16–500-fold increase in the
expression of receptor-type tyrosine-protein phosphatase-ζ (RPTPζ; also known as
PTPRZ1). RPTPζ participates in multiple signalling pathways146,147. The authors observed
that, concomitantly with RPTPζ overexpression, nuclear β-catenin expression was
increased, with significant activation of the β-catenin target genes cyclin D1 (Ccnd1), Jun,
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Myc, fos-like antigen 1 (Fosl1; also known as Fra1) and Cd44. These studies in kidney
cancer, together with results indicating that iron potentiates WNT signalling in colorectal
cancer134 (discussed above), suggest that the activation of WNT signalling may be a
common pathway through which iron contributes to malignant progression.
Iron is a target for cancer therapy and prevention
Iron chelators are natural or synthetic small molecules that bind iron with a high affinity.
Several iron chelators, such as desferoxamine (DFO), deferiprone and deferasirox are used
clinically for the treatment of patients with iron overload disorders. The avidity of cancer
cells for iron has led to the question of whether iron chelators could be used in cancer
therapy. Two broad strategies have been explored. The first has been to use iron chelators to
deplete cancer cells of iron. A second, more recent strategy has been to use chelators that
facilitate the redox cycling of iron to generate cytotoxic ROS within tumours. Both
approaches are currently being pursued.
Owing to its safety profile, early studies of the anti-cancer activity of iron chelators used
DFO. DFO caused leukaemic cytoreduction in a patient with acute leukaemia148 and a 20%
overall response rate in a study of ten patients with treatment-refractory metastatic
hepatocellular carcinoma149, prompting an extended search for more effective iron chelators
(reviewed in REFS 112,150). Iron chelators that are under preclinical or early clinical
investigation as anticancer therapeutics are listed in TABLE 2. An unanticipated recent
discovery has been that iron chelators induce the expression of the metastasis suppressor
NMYC downstream regulated gene 1 (NDRG1)151. NDRG1 expression is decreased in a
number of cancers, and its overexpression reduces the invasion and metastasis of some
cancers — for example, prostate and colorectal cancer — but not of all cancers152. The
induction of NDRG1 was associated with the inhibition of the epithelial–mesenchymal
transition (EMT) in colon and prostate cancer cells153, suggesting the exciting possibility
that iron chelators may not only inhibit the growth of primary tumours, but may also
potentially inhibit metastatic spread.
New-generation single-chain antibodies targeted towards TFR1 that effectively deplete
intracellular iron are also under investigation; these have been shown to effectively
antagonize the growth of leukaemia in mice154. The use of TFR1 as a tumour-targeting
ligand for the delivery of numerous antitumour cytotoxics is also being actively pursued.
Examples include TF–chemotherapeutic drug conjugates, such as TF–doxorubicin, TF–
cisplatin and TF–chlorambucil; TF–cytotoxin conjugates such as TF–ricin A chain and TF–
diptheria toxin (TF-CRM107); and TF-conjugated micelles, dendrimers and other larger
moieties carrying antineoplastic nucleic acids30.
The development of iron chelators or other iron-restrictive strategies as chemopreventives
represents additional opportunities. Curcumin, a pigment found in turmeric that is
commonly used in curry and with a long history of use in traditional Indian Ayurvedic
medicine155, is a cancer chemopreventive and some of its activity may be attributable to its
ability to che-late iron156,157. The excellent safety profile of curcumin is congruent with its
long-term use as a chemopreventive150,155. Curcumin has also served as a springboard for
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the design of new and potentially more potent synthetic chemopreventive agents158,159. The
iron-binding activity of garcinol, a structurally similar substance that is derived from shrubs
native to India and Southeast Asia, may also account for its ability to prevent oral
tumours160.
Conclusions
Substantive and transformative evidence, much of it obtained in the past 5 years, implicates
changes in the uptake and management of iron as crucial features of cancer, and suggests
that altered iron metabolism is a key metabolic ‘hallmark of cancer’ (REF. 161). These
advances are both conceptual and factual. The over-arching theme that emerges is that iron
has roles in all aspects of cancer development, including the tumour microenvironment and
metastasis. Further, the iron biology of a tumour, as evidenced by the expression pattern of
‘iron genes’ in malignant tumours, is not simply associated with cancer, but also has a role
of sufficient magnitude to indicate a patient’s chances of survival. In breast cancer, for
example, almost 50% of all genes involved in the regulation or maintenance of iron
metabolism were significantly associated with clinical outcome71. Thus, iron is more deeply
embedded in tumour cell biology than has been previously understood.
Consistent with this scenario, a plethora of iron-regulatory proteins have recently been
linked to cancer. The precise contributions of this expanded roster of players are not yet
fully understood, but clearly represent new directions for investigation. For example, the
recently appreciated role of iron–sulphur cluster biogenesis in DNA repair, replication and
modification suggests that this will have an important impact on tumour initiation and
progression. Supporting this contention, iron–sulphur cluster scaffold homologue (ISCU),
iron–sulphur cluster assembly 1 homologue (ISCA1) and cytosolic iron– sulphur protein
assembly 1 (CIAO1) were significantly associated with the survival of cancer patients71.
Clear mechanistic links between iron and signalling in cancer cells are emerging. The
identification of the WNT signalling pathway as a key target of iron is perhaps the most
important recent example. The identification of this pathway by multiple different
laboratories using unrelated approaches suggests that further interrogation of this
relationship will yield more detailed mechanistic insights, as well as opportunities for
therapeutic intervention.
Just as our biosphere has evolved in an iron-limited environment, living organisms have
evolved to tightly partition and limit available iron. Another emerging theme is that tumours
create their own iron-rich micro-environment to evade constraints that are imposed by
limited systemic iron availability. Compared with non-malignant mammary tissue, breast
tumours downregu-late ferroportin and upregulate hepcidin, subverting normal homeostatic
controls to acquire more than their fair share of iron71. This recent evidence for autocrine or
paracrine regulation of iron in the tumour micro-environment represents a new paradigm in
iron biology. Cancer cells can also invert the normal relationship between iron and its
regulatory proteins: in the Apcmin/+ mouse model of colorectal cancer, iron induces the
expression of TFR1 and DMT1 in the intestine, increasing the iron content of these cells50.
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This induction of TFR1 expression by iron is opposite to what is observed during the
maintenance of normal iron homeostasis (in which iron decreases TFR1 expression).
There are many remaining questions that need to be addressed. For example, are changes to
iron-regulatory proteins passengers or drivers in malignant change? Some iron-regulatory
proteins may be oncogenic, such as IRP2; others, such as IRP1 and frataxin, may be tumour
suppressive. Enhanced iron acquisition and/or retention are characteristics of many tumours,
and tumour growth can be directly affected simply by manipulating the expression of TFR1
(REFS 70,154), ferritin162,163 or ferroportin69. Thus, altered levels of at least some iron-
regulatory proteins do not merely accompany malignant change, but directly drive tumour
growth.
What prognostic and therapeutic opportunities do the connections between iron and cancer
provide? Studies in breast cancer suggest that the expression of genes and proteins of iron
metabolism could be used to evaluate cancer prognosis and to guide therapy69,71. Ferritin
may be a useful prognostic indicator in cancer: although increased ferritin levels in the
serum are not tumour-specific164, recent studies have suggested that FTL expression in
tumour-associated macrophages may be prognostic in node-negative breast cancer165;
ferritin present in breath condensate has even been suggested as a potential prognostic
indicator for non-small-cell lung cancer166. Therapeutically, targeting iron-sensitive nodes
of growth-regulatory pathways may provide a novel strategy. In addition, iron chelators are
a promising approach to targeting iron-regulatory pathways. Although reducing tumour cell
iron levels without lowering systemic iron may be a challenge, the conjugation of chelators
to tumour-targeting ligands could be used to concentrate chelators at the tumour site to
overcome this problem. A complementary strategy would be to focus on chelators that foster
oxygen radical formation, as these would be more, rather than less, effective in an
environment that is rich in iron112. Further, the discovery that iron chelators target the WNT
pathway137,138,167 may offer a specific new way to direct iron chelator therapy: tumours
with deregulated WNT signalling may represent particularly vulnerable targets.
Much has been done; and much more needs to be done. A more detailed understanding of
specific pathways and proteins that are targeted by iron depletion is needed to optimize
therapies targeted towards iron depletion. A more comprehensive picture of exactly how
iron metabolism is altered in malignant cells would be of substantial benefit for identifying
key points of control that can be therapeutically manipulated; systems biology approaches
may be helpful in this regard168–170. The rich vein of iron metabolism will be fully mined
when we understand not only normal pathways of iron homeostasis, but also the
perturbations of these pathways that initiate and sustain cancer.
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Glossary
Fenton reaction A chemical reaction in which ferrous iron reacts with hydrogen
peroxide to produce the hydroxyl radical. Iron oxidized during
this reaction can be reduced back to ferrous iron in the presence
of superoxide (a by-product of respiration). The sum of these
reactions is the iron-catalysed formation of hydroxyl radicals
from superoxide (termed the Haber–Weiss reaction).
Siderophore A low molecular mass compound that has a high affinity for
chelating iron.
Iron–sulphur clusters Assemblies of iron and inorganic sulphur that function as
protein cofactors.
Hereditary
haemochromatosis
Inherited disorder caused by mutations in several different
genes that leads to the accumulation of iron to excess levels in
parenchymal tissues.
Phlebotomy Drawing or removing blood from the circulation.
Enterocytes Intestinal epithelial cells that have major roles in the absorption
of nutrients, including iron.
Iron recycling Reuse of cellular iron. Typically occurs through the catabolism
of senescent red blood cells by macrophages of the liver and
spleen.
Friedreich’s ataxia Inherited disorder of the neurodegenerative system.
Warburg effect The propensity of cancer cells to shift from aerobic respiration
to glycolysis for the generation of ATP, even in the presence of
adequate oxygen levels. The name derives from the hypothesis
proposed by Otto Warburg in 1924 that cancer is driven by the
non-oxidative breakdown of glucose.
Acyl hydrazones Chemical substances containing oxygen and nitrogen donor
ligands that coordinate iron.
Cytoreduction Decreasing the number of cancer cells.
References
1. Crichton, R. Iron Metabolism: from Molecular Mechanisms to Cinical Consequences. John Wiley
and Sons; 2009. p. 17-58.
2. Inoue S, Kawanishi S. Hydroxyl radical production and human DNA damage induced by ferric
nitrilotriacetate and hydrogen peroxide. Cancer Res. 1987; 47:6522–6527. [PubMed: 2824034]
3. Dizdaroglu M, Rao G, Halliwell B, Gajewski E. Damage to the DNA bases in mammalian
chromatin by hydrogen peroxide in the presence of ferric and cupric ions. Arch. Biochem. Biophys.
1991; 285:317–324. [PubMed: 1654771]
4. Dizdaroglu M, Jaruga P. Mechanisms of free radical-induced damage to DNA. Free Radic. Res.
2012; 46:382–419. [PubMed: 22276778]
Torti and Torti Page 15
Nat Rev Cancer. Author manuscript; available in PMC 2014 May 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
5. Campbell JA. Effects of precipitated silica and of iron oxide on the incidence of primary lung
tumours in mice. Br. Med. J. 1940; 2:275–280. [PubMed: 20783265]
6. Richmond HG. Induction of sarcoma in the rat by iron-dextran complex. Br. Med. J. 1959; 1:947–
949. [PubMed: 13638595]
7. Hann HW, Stahlhut MW, Blumberg BS. Iron nutrition and tumor growth: decreased tumor growth
in iron-deficient mice. Cancer Res. 1988; 48:4168–4170. [PubMed: 3390810]
8. Hann HW, Stahlhut MW, Menduke H. Iron enhances tumor growth. Observation on spontaneous
mammary tumors in mice. Cancer. 1991; 68:2407–2410. [PubMed: 1657354]
9. Stevens RG, Graubard BI, Micozzi MS, Neriishi K, Blumberg BS. Moderate elevation of body iron
level and increased risk of cancer occurrence and death. Int. J. Cancer. 1994; 56:364–369.
[PubMed: 8314323]
10. Stevens RG, Jones DY, Micozzi MS, Taylor PR. Body iron stores and the risk of cancer. New
Engl. J. Med. 1988; 319:1047–1052. [PubMed: 3173433]
11. van Asperen IA, Feskens EJ, Bowles CH, Kromhout D. Body iron stores and mortality due to
cancer and ischaemic heart disease: a 17-year follow-up study of elderly men and women. Int. J.
Epidemiol. 1995; 24:665–670. [PubMed: 8550261]
12. Knekt P, et al. Body iron stores and risk of cancer. Int. J. Cancer. 1994; 56:379–382. [PubMed:
8314326]
13. Wu T, Sempos CT, Freudenheim JL, Muti P, Smit E. Serum iron, copper and zinc concentrations
and risk of cancer mortality in US adults. Ann. Epidemiol. 2004; 14:195–201. [PubMed:
15036223]
14. Nelson RL. Iron and colorectal cancer risk: human studies. Nutr. Rev. 2001; 59:140–148.
[PubMed: 11396694]
15. Kabat GC, Miller AB, Jain M, Rohan TE. Dietary iron and haem iron intake and risk of
endometrial cancer: a prospective cohort study. Br. J. Cancer. 2008; 98:194–198. [PubMed:
18059399]
16. Mursu J, Robien K, Harnack LJ, Park K, Jacobs DR Jr. Dietary supplements and mortality rate in
older women: the Iowa Women’s Health Study. Arch. Intern. Med. 2011; 171:1625–1633.
[PubMed: 21987192]
17. Ward MH, et al. Heme iron from meat and risk of adenocarcinoma of the esophagus and stomach.
Eur. J. Cancer Prev. 2012; 21:134–138. [PubMed: 22044848]
18. Cross AJ, Pollock JR, Bingham SA. Haem, not protein or inorganic iron, is responsible for
endogenous intestinal N-nitrosation arising from red meat. Cancer Res. 2003; 63:2358–2360.
[PubMed: 12750250]
19. Choi JY, et al. Iron intake, oxidative stress-related genes (MnSOD and MPO) and prostate cancer
risk in CARET cohort. Carcinogenesis. 2008; 29:964–970. [PubMed: 18296681]
20. Hong CC, et al. Genetic variability in iron-related oxidative stress pathways (Nrf2, NQ01, NOS3,
and HO-1), iron intake, and risk of postmenopausal breast cancer. Cancer Epidemiol. Biomarkers
Prev. 2007; 16:1784–1794. [PubMed: 17726138]
21. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment.
Gastroenterology. 2010; 139:393–408. [PubMed: 20542038]
22. Bradbear RA, et al. Cohort study of internal malignancy in genetic hemochromatosis and other
chronic nonalcoholic liver diseases. J. Natl Cancer Inst. 1985; 75:81–84. [PubMed: 2989605]
23. Milman N, et al. Clinically overt hereditary hemochromatosis in Denmark 1948-1985:
epidemiology, factors of significance for long-term survival, and causes of death in 179 patients.
Ann. Hematol. 2001; 80:737–744. [PubMed: 11797115]
24. Elmberg M, et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree
relatives. Gastroenterology. 2003; 125:1733–1741. [PubMed: 14724826]
25. Niederau C, et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with
primary hemochromatosis. N. Engl. J. Med. 1985; 313:1256–1262. [PubMed: 4058506]
26. Hsing AW, et al. Cancer risk following primary hemochromatosis: a population-based cohort study
in Denmark. Int. J. Cancer. 1995; 60:160–162. [PubMed: 7829208]
Torti and Torti Page 16
Nat Rev Cancer. Author manuscript; available in PMC 2014 May 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
27. Osborne NJ, et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer.
Hepatology. 2010; 51:1311–1318. [PubMed: 20099304]
28. Edgren G, et al. Donation frequency, iron loss, and risk of cancer among blood donors. J. Natl
Cancer Inst. 2008; 100:572–579. [PubMed: 18398098]
29. Andrews NC. Forging a field: the golden age of iron biology. Blood. 2008; 112:219–230.
[PubMed: 18606887] Excellent overall review of recent advances in iron biology.
30. Daniels TR, et al. The transferrin receptor and the targeted delivery of therapeutic agents against
cancer. Biochim. Biophys. Acta. 2012; 1820:291–317. [PubMed: 21851850] Summary of past and
current strategies used to target TFR1 for anticancer therapy.
31. Brooks D, et al. Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6.
Clin. Cancer Res. 1995; 1:1259–1265. [PubMed: 9815920]
32. Taetle R, Castagnola J, Mendelsohn J. Mechanisms of growth inhibition by anti-transferrin
receptor monoclonal antibodies. Cancer Res. 1986; 46:1759–1763. [PubMed: 3004704]
33. Ohgami RS, et al. Identification of a ferrireductase required for efficient transferrin-dependent iron
uptake in erythroid cells. Nature Genet. 2005; 37:1264–1269. [PubMed: 16227996]
34. Knutson MD. Steap proteins: implications for iron and copper metabolism. Nutr. Rev. 2007;
65:335–340. [PubMed: 17695374]
35. Leng X, Wu Y, Arlinghaus RB. Relationships of lipocalin 2 with breast tumorigenesis and
metastasis. J. Cell. Physiol. 2011; 226:309–314. [PubMed: 20857428]
36. Zhang Y, Fan Y, Mei Z. NGAL and NGALR overexpression in human hepatocellular carcinoma
toward a molecular prognostic classification. Cancer Epidemiol. 2012; 36:e294–e299. [PubMed:
22728279]
37. Leung L, et al. Lipocalin2 promotes invasion, tumorigenicity and gemcitabine resistance in
pancreatic ductal adenocarcinoma. PLoS ONE. 2012; 7:e46677. [PubMed: 23056397]
38. Saha R, Saha N, Donofrio RS, Bestervelt LL. Microbial siderophores: a mini review. J. Basic
Microbiol. Jun 26.2012 (doi:10.1002/jobm.201100552).
39. Bao G, et al. Iron traffics in circulation bound to a siderocalin (Ngal)-catechol complex. Nature
Chem. Biol. 2010; 6:602–609. [PubMed: 20581821]
40. Devireddy LR, Hart DO, Goetz DH, Green MR. A mammalian siderophore synthesized by an
enzyme with a bacterial homolog involved in enterobactin production. Cell. 2010; 141:1006–1017.
[PubMed: 20550936] References 39 and 40 were the first to identify endogenous mammalian
siderophores.
41. Fernandez CA, et al. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin
complex plays a role in breast tumor growth and is present in the urine of breast cancer patients.
Clin. Cancer Res. 2005; 11:5390–5395. [PubMed: 16061852]
42. Yang J, McNeish B, Butterfield C, Moses MA. Lipocalin 2 is a novel regulator of angiogenesis in
human breast cancer. FASEB J. 2012; 27:45–50. [PubMed: 22982376]
43. Berger T, Cheung CC, Elia AJ, Mak TW. Disruption of the Lcn2 gene in mice suppresses primary
mammary tumor formation but does not decrease lung metastasis. Proc. Natl Acad. Sci. USA.
2010; 107:2995–3000. [PubMed: 20133630]
44. Cramer EP, et al. No effect of NGAL/lipocalin-2 on aggressiveness of cancer in the MMTV-
PyMT/FVB/N mouse model for breast cancer. PLoS ONE. 2012; 7:e39646. [PubMed: 22737251]
45. Lee HJ, et al. Ectopic expression of neutrophil gelatinase-associated lipocalin suppresses the
invasion and liver metastasis of colon cancer cells. Int. J. Cancer. 2006; 118:2490–2497. [PubMed:
16381001]
46. Sun Y, et al. NGAL expression is elevated in both colorectal adenoma-carcinoma sequence and
cancer progression and enhances tumorigenesis in xenograft mouse models. Clin. Cancer Res.
2011; 17:4331–4340. [PubMed: 21622717]
47. Bauer M, et al. Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis
in human primary breast cancer. Breast Cancer Res. Treat. 2008; 108:389–397. [PubMed:
17554627]
48. Wenners AS, et al. Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to
neoadjuvant chemotherapy and clinical outcome in primary human breast cancer. PLoS ONE.
2012; 7:e45826. [PubMed: 23056218]
Torti and Torti Page 17
Nat Rev Cancer. Author manuscript; available in PMC 2014 May 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
49. Wu KJ, Polack A, Dalla-Favera R. Coordinated regulation of iron-controlling genes, H-ferritin and
IRP2, by c-MYC. Science. 1999; 283:676–679. [PubMed: 9924025]
50. Radulescu S, et al. Luminal iron levels govern intestinal tumorigenesis after apc loss in vivo. Cell
Rep. 2012; 2:270–282. [PubMed: 22884366] This paper provides a mechanistic explanation of
how excess iron contributes to intestinal tumorigenesis.
51. Tsuji Y, Kwak E, Saika T, Torti SV, Torti FM. Preferential repression of the H subunit of ferritin
by adenovirus E1A in NIH-3T3 mouse fibroblasts. J. Biol. Chem. 1993; 268:7270–7275.
[PubMed: 8463262]
52. Kakhlon O, Gruenbaum Y, Cabantchik ZI. Repression of ferritin expression modulates cell
responsiveness to H-ras-induced growth. Biochem. Soc. Trans. 2002; 30:777–780. [PubMed:
12196194]
53. Kakhlon O, Gruenbaum Y, Cabantchik ZI. Ferritin expression modulates cell cycle dynamics and
cell responsiveness to H-ras-induced growth via expansion of the labile iron pool. Biochem. J.
2002; 363:431–436. [PubMed: 11964143]
54. Zhang F, Wang W, Tsuji Y, Torti SV, Torti FM. Post-transcriptional modulation of iron
homeostasis during p53-dependent growth arrest. J. Biol. Chem. 2008; 283:33911–33918.
[PubMed: 18819919]
55. Tong WH, et al. The glycolytic shift in fumaratehydratase-deficient kidney cancer lowers AMPK
levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell. 2011; 20:315–
327. [PubMed: 21907923]
56. Shpyleva SI, et al. Role of ferritin alterations in human breast cancer cells. Breast Cancer Res.
Treat. 2011; 126:63–71. [PubMed: 20390345]
57. Liu X, et al. Heavy chain ferritin siRNA delivered by cationic liposomes increases sensitivity of
cancer cells to chemotherapeutic agents. Cancer Res. 2011; 71:2240–2249. [PubMed: 21385903]
58. Karin M. Nuclear factor-κB in cancer development and progression. Nature. 2006; 441:431–436.
[PubMed: 16724054]
59. Torti SV, et al. The molecular cloning and characterization of murine ferritin heavy chain, a tumor
necrosis factor-inducible gene. J. Biol. Chem. 1988; 263:12638–12644. [PubMed: 3410854]
60. Kwak EL, Larochelle DA, Beaumont C, Torti SV, Torti FM. Role for NF-kappa B in the
regulation of ferritin H by tumor necrosis factor-alpha. J. Biol. Chem. 1995; 270:15285–15293.
[PubMed: 7797515]
61. Pham CG, et al. Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced
apoptosis by suppressing reactive oxygen species. Cell. 2004; 119:529–542. [PubMed: 15537542]
62. Ruddell RG, et al. Ferritin functions as a proinflammatory cytokine via iron-independent protein
kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells. Hepatology.
2009; 49:887–900. [PubMed: 19241483]
63. Alkhateeb AA, Han B, Connor JR. Ferritin stimulates breast cancer cells through an iron-
independent mechanism and is localized within tumor-associated macrophages. Breast Cancer
Res. Treat. 2013; 137:733–744. [PubMed: 23306463]
64. Cortes DF, et al. Differential gene expression in normal and transformed human mammary
epithelial cells in response to oxidative stress. Free Radic. Biol. Med. 2011; 50:1565–1574.
[PubMed: 21397008]
65. Nemeth E, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its
internalization. Science. 2004; 306:2090–2093. [PubMed: 15514116] Ground-breaking study
demonstrating that hepcidin binds to ferroportin and triggers its degradation.
66. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim. Biophys. Acta. 2012; 1823:1434–
1443. [PubMed: 22306005]
67. Ward DM, Kaplan J. Ferroportin-mediated iron transport: expression and regulation. Biochim.
Biophys. Acta. 2012; 1823:1426–1433. [PubMed: 22440327]
68. Lonnerdal B. Trace element transport in the mammary gland. Annu. Rev. Nutr. 2007; 27:165–177.
[PubMed: 17506666]
69. Pinnix ZK, et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci
Transl Med. 2010; 2:43ra56. This paper demonstrates that levels of ferroportin affect breast cancer
Torti and Torti Page 18
Nat Rev Cancer. Author manuscript; available in PMC 2014 May 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
cell growth, are altered in patients with breast cancer and affect the prognosis of patients with
breast cancer.
70. Jiang XP, Elliott RL, Head JF. Manipulation of iron transporter genes results in the suppression of
human and mouse mammary adenocarcinomas. Anticancer Res. 2010; 30:759–765. [PubMed:
20392994]
71. Miller LD, et al. An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res.
2011; 71:6728–6737. [PubMed: 21875943]
72. Weiss G, Goodnough LT. Anemia of chronic disease. N. Engl. J. Med. 2005; 352:1011–1023.
[PubMed: 15758012]
73. Weinberg ED, Miklossy J. Iron withholding: a defense against disease. J. Alzheimers Dis. 2008;
13:451–463. [PubMed: 18487852]
74. Weinberg ED. Iron withholding: a defense against infection and neoplasia. Physiol. Rev. 1984;
64:65–102. [PubMed: 6420813]
75. Maes K, et al. In anemia of multiple myeloma, hepcidin is induced by increased bone
morphogenetic protein 2. Blood. 2010; 116:3635–3644. [PubMed: 20679527]
76. Hohaus S, et al. Anemia in Hodgkin’s lymphoma: the role of interleukin-6 and hepcidin. J. Clin.
Oncol. 2010; 28:2538–2543. [PubMed: 20406921]
77. Hubert N, Hentze MW. Previously uncharacterized isoforms of divalent metal transporter
(DMT)-1: implications for regulation and cellular function. Proc. Natl Acad. Sci. USA. 2002;
99:12345–12350. [PubMed: 12209011]
78. Galy B, Ferring-Appel D, Kaden S, Grone HJ, Hentze MW. Iron regulatory proteins are essential
for intestinal function and control key iron absorption molecules in the duodenum. Cell. Metab.
2008; 7:79–85. [PubMed: 18177727]
79. Maffettone C, Chen G, Drozdov I, Ouzounis C, Pantopoulos K. Tumorigenic properties of iron
regulatory protein 2 (IRP2) mediated by its specific 73-amino acids insert. PLoS ONE. 2010;
5:e10163. [PubMed: 20405006] This work suggests that IRPs can modify tumour growth in ways
that are independent of their effects on iron metabolism.
80. Chen G, Fillebeen C, Wang J, Pantopoulos K. Overexpression of iron regulatory protein 1
suppresses growth of tumor xenografts. Carcinogenesis. 2007; 28:785–791. [PubMed: 17127713]
81. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;
454:436–444. [PubMed: 18650914]
82. Recalcati S, et al. Differential regulation of iron homeostasis during human macrophage polarized
activation. Eur. J. Immunol. 2010; 40:824–835. [PubMed: 20039303]
83. Corna G, et al. Polarization dictates iron handling by inflammatory and alternatively activated
macrophages. Haematologica. 2010; 95:1814–1822. [PubMed: 20511666]
84. Cohen LA, et al. Serum ferritin is derived primarily from macrophages through a nonclassical
secretory pathway. Blood. 2010; 116:1574–1584. [PubMed: 20472835]
85. Han J, et al. Iron uptake mediated by binding of H-ferritin to the TIM-2 receptor in mouse cells.
PLoS ONE. 2011; 6:e23800. [PubMed: 21886823]
86. Li L, et al. Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc.
Natl Acad. Sci. USA. 2010; 107:3505–3510. [PubMed: 20133674]
87. Coffman LG, et al. Regulatory effects of ferritin on angiogenesis. Proc. Natl Acad. Sci. USA.
2009; 106:570–575. [PubMed: 19126685] This paper demonstrates that extracellular ferritin can
antagonize the activity of endogenous antiangiogenic proteins.
88. Tesfay L, Huhn AJ, Hatcher H, Torti FM, Torti SV. Ferritin blocks inhibitory effects of two-chain
high molecular weight kininogen (HKa) on adhesion and survival signaling in endothelial cells.
PLoS ONE. 2012; 7:e40030. [PubMed: 22768328]
89. Ackroyd R, Shorthouse AJ, Stephenson TJ. Gastric carcinoma in siblings with Friedreich’s ataxia.
Eur. J. Surg. Oncol. 1996; 22:301–303. [PubMed: 8654617]
90. Kidd A, et al. Breast cancer in two sisters with Friedreich’s ataxia. Eur. J. Surg. Oncol. 2001;
27:512–514. [PubMed: 11504527]
Torti and Torti Page 19
Nat Rev Cancer. Author manuscript; available in PMC 2014 May 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
91. Lill R, et al. The role of mitochondria in cellular iron-sulfur protein biogenesis and iron
metabolism. Biochim. Biophys. Acta. 2012; 1823:1491–1508. [PubMed: 22609301] Review of
recent advances in mechanisms of iron–sulphur cluster biogenesis.
92. Babcock M, et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of
frataxin. Science. 1997; 276:1709–1712. [PubMed: 9180083]
93. Shoichet SA, et al. Frataxin promotes antioxidant defense in a thiol-dependent manner resulting in
diminished malignant transformation in vitro. Hum. Mol. Genet. 2002; 11:815–821. [PubMed:
11929854]
94. Thierbach R, et al. Targeted disruption of hepatic frataxin expression causes impaired
mitochondrial function, decreased life span and tumor growth in mice. Hum. Mol. Genet. 2005;
14:3857–3864. [PubMed: 16278235]
95. Schulz TJ, et al. Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer
growth: Otto Warburg revisited. J. Biol. Chem. 2006; 281:977–981. [PubMed: 16263703]
96. Thierbach R, et al. The Friedreich’s ataxia protein frataxin modulates DNA base excision repair in
prokaryotes and mammals. Biochem. J. 2010; 432:165–172. [PubMed: 20819074]
97. Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour
growth and progression. Nature Rev. Cancer. 2012; 12:9–22. [PubMed: 22169972]
98. Semenza GL. HIF-1: upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev.
2010; 20:51–56. [PubMed: 19942427]
99. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-
inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction.
Blood. 1993; 82:3610–3615. [PubMed: 8260699]
100. Tacchini L, Bianchi L, Bernelli-Zazzera A, Cairo G. Transferrin receptor induction by hypoxia.
HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J.
Biol. Chem. 1999; 274:24142–24146. [PubMed: 10446187]
101. Lok CN, Ponka P. Identification of a hypoxia response element in the transferrin receptor gene. J.
Biol. Chem. 1999; 274:24147–24152. [PubMed: 10446188]
102. Lee PJ, et al. Hypoxia-inducible factor-1 mediates transcriptional activation of the heme
oxygenase-1 gene in response to hypoxia. J. Biol. Chem. 1997; 272:5375–5381. [PubMed:
9038135]
103. Mukhopadhyay CK, Mazumder B, Fox PL. Role of hypoxia-inducible factor-1 in transcriptional
activation of ceruloplasmin by iron deficiency. J. Biol. Chem. 2000; 275:21048–21054.
[PubMed: 10777486]
104. Peyssonnaux C, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription
factors (HIFs). J. Clin. Invest. 2007; 117:1926–1932. [PubMed: 17557118]
105. Mastrogiannaki M, et al. HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. J.
Clin. Invest. 2009; 119:1159–1166. [PubMed: 19352007] This paper demonstrates the role of
HIF2α in iron absorption.
106. Shah YM, Matsubara T, Ito S, Yim SH, Gonzalez FJ. Intestinal hypoxia-inducible transcription
factors are essential for iron absorption following iron deficiency. Cell. Metab. 2009; 9:152–164.
[PubMed: 19147412]
107. Xue X, et al. Hypoxia-inducible factor-2alpha activation promotes colorectal cancer progression
by dysregulating iron homeostasis. Cancer Res. 2012; 72:2285–2293. [PubMed: 22419665]
108. Terada N, Or R, Szepesi A, Lucas JJ, Gelfand EW. Definition of the roles for iron and essential
fatty acids in cell cycle progression of normal human T lymphocytes. Exp. Cell Res. 1993;
204:260–267. [PubMed: 8440323]
109. Thelander L, Graslund A. Mechanism of inhibition of mammalian ribonucleotide reductase by the
iron chelate of 1-formylisoquinoline thiosemicarbazone. Destruction of the tyrosine free radical
of the enzyme in an oxygen-requiring reaction. J. Biol. Chem. 1983; 258:4063–4066. [PubMed:
6300073]
110. Thelander L, Graslund A, Thelander M. Continual presence of oxygen and iron required for
mammalian ribonucleotide reduction: possible regulation mechanism. Biochem. Biophys. Res.
Commun. 1983; 110:859–865. [PubMed: 6340669]
Torti and Torti Page 20
Nat Rev Cancer. Author manuscript; available in PMC 2014 May 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
111. Martin LK, et al. A dose escalation and pharmacodynamic study of triapine and radiation in
patients with locally advanced pancreas cancer. Int. J. Radiat. Oncol. Biol. Phys. 2012; 84:e475–
e481. [PubMed: 22818416]
112. Yu Y, et al. Iron chelators for the treatment of cancer. Curr. Med. Chem. 2012; 19:2689–2702.
[PubMed: 22455580] Recent summary of progress and challenges in the development of iron
chelators as anticancer therapeutics.
113. Tanaka H, et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle
checkpoint for DNA damage. Nature. 2000; 404:42–49. [PubMed: 10716435]
114. Shao J, et al. In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit
of human ribonucleotide reductase. Cancer Res. 2004; 64:1–6. [PubMed: 14729598]
115. Smith P, et al. 2.6 A X-ray crystal structure of human p53R2, a p53-inducible ribonucleotide
reductase. Biochemistry. 2009; 48:11134–11141. [PubMed: 19728742]
116. Netz DJ, et al. Eukaryotic DNA polymerases require an iron-sulfur cluster for the formation of
active complexes. Nature Chem. Biol. 2012; 8:125–132. [PubMed: 22119860]
117. Veatch JR, McMurray MA, Nelson ZW, Gottschling DE. Mitochondrial dysfunction leads to
nuclear genome instability via an iron-sulfur cluster defect. Cell. 2009; 137:1247–1258.
[PubMed: 19563757]
118. Rudolf J, Makrantoni V, Ingledew WJ, Stark MJR, White MF. The DNA repair helicases XPD
and FancJ have essential iron-sulfur domains. Mol. Cell. 2006; 23:801–808. [PubMed:
16973432]
119. Karanja KK, Cox SW, Duxin JP, Stewart SA, Campbell JL. DNA2 and EXO1 in replication-
coupled, homology-directed repair and in the interplay between HDR and the FA/BRCA
network. Cell Cycle. 2012; 11:3983–3996. [PubMed: 22987153]
120. Barber LJ, et al. RTEL1 maintains genomic stability by suppressing homologous recombination.
Cell. 2008; 135:261–271. [PubMed: 18957201]
121. Stehling O, et al. MMS19 assembles iron-sulfur proteins required for DNA metabolism and
genomic integrity. Science. 2012; 337:195–199. [PubMed: 22678362] Identification of MMS19
as a scaffolding protein involved in the assembly of a subset of iron–sulphur cluster-containing
proteins involved in genome integrity, and demonstration of the role of this pathway in the
response to DNA damage.
122. Lorsbach RB, et al. TET1, a member of a novel protein family, is fused to MLL in acute myeloid
leukemia containing the t(10;11)(q22;q23). Leukemia. 2003; 17:637–641. [PubMed: 12646957]
123. Thomson J, et al. Non-genotoxic carcinogen exposure induces defined changes in the 5-
hydroxymethylome. Genome Biol. 2012; 13:R93. [PubMed: 23034186]
124. Tahiliani M, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian
DNA by MLL partner TET1. Science. 2009; 324:930–935. [PubMed: 19372391]
125. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nature Rev.
Cancer. 2009; 9:153–166. [PubMed: 19238148]
126. Kulp KS, Green SL, Vulliet PR. Iron deprivation inhibits cyclin-dependent kinase activity and
decreases cyclin D/CDK4 protein levels in asynchronous MDA-MB-453 human breast cancer
cells. Exp. Cell Res. 1996; 229:60–68. [PubMed: 8940249]
127. Nurtjahja-Tjendraputra E, Fu D, Phang JM, Richardson DR. Iron chelation regulates cyclin D1
expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood.
2007; 109:4045–4054. [PubMed: 17197429]
128. Ornstein DL, Zacharski LR. Iron stimulates urokinase plasminogen activator expression and
activates NF-kappa B in human prostate cancer cells. Nutr. Cancer. 2007; 58:115–126. [PubMed:
17571974]
129. Tsukamoto H. Iron regulation of hepatic macrophage TNFalpha expression. Free Radic. Biol.
Med. 2002; 32:309–313. [PubMed: 11841920]
130. Pang H, et al. Crystal structure of human pirin: an iron-binding nuclear protein and transcription
cofactor. J. Biol. Chem. 2004; 279:1491–1498. [PubMed: 14573596]
131. Yu Y, Richardson DR. Cellular iron depletion stimulates the JNK and p38 MAPK signaling
transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1. J. Biol.
Chem. 2011; 286:15413–15427. [PubMed: 21378396]
Torti and Torti Page 21
Nat Rev Cancer. Author manuscript; available in PMC 2014 May 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
132. Polakis P. Wnt signaling and cancer. Genes Dev. 2000; 14:1837–1851. [PubMed: 10921899]
133. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nature Rev.
Cancer. 2008; 8:387–398. [PubMed: 18432252]
134. Brookes MJ, et al. A role for iron in Wnt signalling. Oncogene. 2008; 27:966–975. [PubMed:
17700530] One of the first papers demonstrating the connection between iron and WNT
signalling.
135. Seril DN, et al. Dietary iron supplementation enhances DSS-induced colitis and associated
colorectal carcinoma development in mice. Dig. Dis. Sci. 2002; 47:1266–1278. [PubMed:
12064801]
136. Ilsley JN, et al. Dietary iron promotes azoxymethane-induced colon tumors in mice. Nutr. Cancer.
2004; 49:162–169. [PubMed: 15489209]
137. Song S, et al. Wnt inhibitor screen reveals iron dependence of beta-catenin signaling in cancers.
Cancer Res. 2011; 71:7628–7639. [PubMed: 22009536]
138. Coombs GS, et al. Modulation of Wnt/beta-catenin signaling and proliferation by a ferrous iron
chelator with therapeutic efficacy in genetically engineered mouse models of cancer. Oncogene.
2012; 31:213–225. [PubMed: 21666721]
139. Ebina Y, et al. Nephrotoxicity and renal cell carcinoma after use of iron- and aluminum-
nitrilotriacetate complexes in rats. J. Natl Cancer Inst. 1986; 76:107–113. [PubMed: 3455733]
140. Hamazaki S, Okada S, Ebina Y, Fujioka M, Midorikawa O. Nephrotoxicity of ferric
nitrilotriacetate. An electron-microscopic and metabolic study. Am. J. Pathol. 1986; 123:343–
350. [PubMed: 3706495]
141. Li JL, Okada S, Hamazaki S, Ebina Y, Midorikawa O. Subacute nephrotoxicity and induction of
renal cell carcinoma in mice treated with ferric nitrilotriacetate. Cancer Res. 1987; 47:1867–
1869. [PubMed: 3815378]
142. Toyokuni S, Mori T, Dizdaroglu M. DNA base modifications in renal chromatin of Wistar rats
treated with a renal carcinogen, ferric nitrilotriacetate. Int. J. Cancer. 1994; 57:123–128.
[PubMed: 8150530]
143. Jiang L, et al. Deletion and single nucleotide substitution at G.:C in the kidney of gpt delta
transgenic mice after ferric nitrilotriacetate treatment. Cancer Sci. 2006; 97:1159–1167.
[PubMed: 16925583]
144. Hiroyasu M, et al. Specific allelic loss of p16 (INK4A) tumor suppressor gene after weeks of
iron-mediated oxidative damage during rat renal carcinogenesis. Am. J. Pathol. 2002; 160:419–
424. [PubMed: 11839561]
145. Akatsuka S, et al. Fenton reaction induced cancer in wild type rats recapitulates genomic
alterations observed in human cancer. PLoS ONE. 2012; 7:e43403. [PubMed: 22952676] This
study establishes a direct connection between iron-induced genomic alterations and cancer.
146. Xu Y, et al. Receptor-type protein tyrosine phosphatase beta (RPTP-beta) directly
dephosphorylates and regulates hepatocyte growth factor receptor (HGFR/Met) function. J. Biol.
Chem. 2011; 286:15980–15988. [PubMed: 21454675]
147. Yacyshyn OK, et al. Tyrosine phosphatase beta regulates angiopoietin-Tie2 signaling in human
endothelial cells. Angiogenesis. 2009; 12:25–33. [PubMed: 19116766]
148. Estrov Z, et al. In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood.
1987; 69:757–761. [PubMed: 3493042]
149. Yamasaki T, Terai S, Sakaida I. Deferoxamine for advanced hepatocellular carcinoma. N. Engl. J.
Med. 2011; 365:576–578. [PubMed: 21830988]
150. Hatcher HC, Singh RN, Torti FM, Torti SV. Synthetic and natural iron chelators: therapeutic
potential and clinical use. Future Med. Chem. 2009; 1:1643–1670. [PubMed: 21425984]
151. Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum
of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl Acad.
Sci. USA. 2006; 103:14901–14906. [PubMed: 17003122]
152. Melotte V, et al. The N-myc downstream regulated gene (NDRG) family: diverse functions,
multiple applications. FASEB J. 2010; 24:4153–4166. [PubMed: 20667976]
Torti and Torti Page 22
Nat Rev Cancer. Author manuscript; available in PMC 2014 May 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
153. Chen Z, et al. The iron chelators Dp44mT and DFO inhibit TGF-beta-induced epithelial-
mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). J.
Biol. Chem. 2012; 287:17016–17028. [PubMed: 22453918]
154. Crepin R, et al. Development of human single-chain antibodies to the transferrin receptor that
effectively antagonize the growth of leukemias and lymphomas. Cancer Res. 2010; 70:5497–
5506. [PubMed: 20530676]
155. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current
clinical trials. Cell. Mol. Life Sci. 2008; 65:1631–1652. [PubMed: 18324353]
156. Jiao Y, et al. Iron chelation in the biological activity of curcumin. Free Radic. Biol. Med. 2006;
40:1152–1160. [PubMed: 16545682]
157. Jiao Y, et al. Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically
active iron chelator. Blood. 2009; 113:462–469. [PubMed: 18815282]
158. Lin L, et al. Antitumor agents. 250. Design and synthesis of new curcumin analogues as potential
anti-prostate cancer agents. J. Med. Chem. 2006; 49:3963–3972. [PubMed: 16789753]
159. Adams BK, et al. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer
and anti-angiogenesis agents. Bioorg. Med. Chem. 2004; 12:3871–3883. [PubMed: 15210154]
160. Chen X, et al. Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced hamster
cheek pouch carcinogenesis by a 5-lipoxygenase inhibitor, garcinol. Nutr. Cancer. 2012;
64:1211–1218. [PubMed: 23137051]
161. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646–674.
[PubMed: 21376230]
162. Cozzi A, et al. Overexpression of wild type and mutated human ferritin H-chain in HeLa cells: in
vivo role of ferritin ferroxidase activity. J. Biol. Chem. 2000; 275:25122–25129. [PubMed:
10833524]
163. Cozzi A, et al. Analysis of the biologic functions of H- and L-ferritins in HeLa cells by
transfection with siRNAs and cDNAs: evidence for a proliferative role of L-ferritin. Blood. 2004;
103:2377–2383. [PubMed: 14615379]
164. Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV. Serum ferritin: Past, present and
future. Biochim. Biophys. Acta. 2010; 1800:760–769. [PubMed: 20304033]
165. Jezequel P, et al. Validation of tumor-associated macrophage ferritin light chain as a prognostic
biomarker in node-negative breast cancer tumors: A multicentric 2004 national PHRC study. Int.
J. Cancer. 2012; 131:426–437. [PubMed: 21898387]
166. Carpagnano GE, et al. Could exhaled ferritin and SOD be used as markers for lung cancer and
prognosis prediction purposes? Eur. J. Clin. Invest. 2012; 42:478–486. [PubMed: 21955247]
167. Kim Y, et al. Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox
olamine in a murine myeloma model. In Vivo. 2011; 25:887–893. [PubMed: 22021681]
168. Chifman J, et al. The core control system of intracellular iron homeostasis: a mathematical model.
J. Theor. Biol. 2012; 300:91–99. [PubMed: 22286016]
169. Laubenbacher R, et al. A systems biology view of cancer. Biochim. Biophys. Acta. 2009;
1796:129–139. [PubMed: 19505535]
170. Hower V, et al. A general map of iron metabolism and tissue-specific subnetworks. Mol. Biosyst.
2009; 5:422–443. [PubMed: 19381358]
171. Sanchez M, Galy B, Muckenthaler MU, Hentze MW. Iron-regulatory proteins limit
hypoxiainducible factor-2alpha expression in iron deficiency. Nature Struct. Mol. Biol. 2007;
14:420–426. [PubMed: 17417656]
172. Abeysinghe RD, et al. p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron
chelator. Carcinogenesis. 2001; 22:1607–1614. [PubMed: 11576999]
173. Lui GY, et al. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity
against human lung tumor xenografts and molecular mechanism of action. Mol. Pharmacol.
2013; 83:179–190. [PubMed: 23074173]
174. Liu YT, et al. Chronic oxidative stress causes amplification and overexpression of ptprz1 protein
tyrosine phosphatase to activate beta-catenin pathway. Am. J. Pathol. 2007; 171:1978–1988.
[PubMed: 18055543]
Torti and Torti Page 23
Nat Rev Cancer. Author manuscript; available in PMC 2014 May 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
175. Ba Q, et al. Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies.
Clin. Cancer Res. 2011; 17:7625–7633. [PubMed: 22052937]
176. Fracanzani AL, et al. Increased cancer risk in a cohort of 230 patients with hereditary
hemochromatosis in comparison to matched control patients with non-iron-related chronic liver
disease. Hepatology. 2001; 33:647–651. [PubMed: 11230745]
177. Hann HW, Stahlhut MW, Hann CL. Effect of iron and desferoxamine on cell growth and in vitro
ferritin synthesis in human hepatoma cell lines. Hepatology. 1990; 11:566–569. [PubMed:
2158479]
178. Boult J, et al. Overexpression of cellular iron import proteins is associated with malignant
progression of esophageal adenocarcinoma. Clin. Cancer Res. 2008; 14:379–387. [PubMed:
18223212]
179. Yue J, et al. Transferrin-conjugated micelles: enhanced accumulation and antitumor effect for
transferrin-receptor-overexpressing cancer models. Mol. Pharm. 2012; 9:1919–1931. [PubMed:
22616905]
180. Brookes MJ, et al. Modulation of iron transport proteins in human colorectal carcinogenesis. Gut.
2006; 55:1449–1460. [PubMed: 16641131]
181. Eberhard Y, et al. Chelation of intracellular iron with the antifungal agent ciclopirox olamine
induces cell death in leukemia and myeloma cells. Blood. 2009; 114:3064–3073. [PubMed:
19589922]
182. Torti SV, et al. Tumor cell cytotoxicity of a novel metal chelator. Blood. 1998; 92:1384–1389.
[PubMed: 9694727]
183. Zhou H, et al. The antitumor activity of the fungicide ciclopirox. Int. J. Cancer. 2010; 127:2467–
2477. [PubMed: 20225320]
184. Greene BT, et al. Activation of caspase pathways during iron chelator-mediated apoptosis. J. Biol.
Chem. 2002; 277:25568–25575. [PubMed: 11980894]
185. Turner J, et al. Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint
kinases, and sensitizes cells to ionizing radiation. Blood. 2005; 106:3191–3199. [PubMed:
16014567]
186. Kovacevic Z, Chikhani S, Lovejoy DB, Richardson DR. Novel thiosemicarbazone iron chelators
induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream
regulated gene 1: a new strategy for the treatment of pancreatic cancer. Mol. Pharmacol. 2011;
80:598–609. [PubMed: 21719465]
187. Yu Y, Suryo Rahmanto Y, Richardson DR. Bp44mT: an orally active iron chelator of the
thiosemicarbazone class with potent anti-tumour efficacy. Br. J. Pharmacol. 2012; 165:148–166.
[PubMed: 21658021]
188. Fukushima T, et al. Iron chelation therapy with deferasirox induced complete remission in a
patient with chemotherapy-resistant acute monocytic leukemia. Anticancer Res. 2011; 31:1741–
1744. [PubMed: 21617233]
189. Yen Y, et al. A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in
combination with gemcitabine for patients with advanced cancer. Cancer Chemother. Pharmacol.
2004; 54:331–342. [PubMed: 15148626]
190. Knox JJ, et al. Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of
the National Cancer Institute of Canada Clinical Trials Group (NCIC IND. Invest. New Drugs.
2007; 25:471–477. [PubMed: 17393073]
191. Ma B, et al. A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone
(3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic
evaluation using peripheral blood mononuclear cells. Invest. New Drugs. 2008; 26:169–173.
[PubMed: 17851637]
192. Chao J, et al. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde
thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a
California Cancer Consortium Study. Cancer Chemother. Pharmacol. 2012; 69:835–843.
[PubMed: 22105720]
Torti and Torti Page 24
Nat Rev Cancer. Author manuscript; available in PMC 2014 May 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
At a glance
• Elemental iron is essential for cellular growth and homeostasis but it is
potentially toxic to cells and tissues. Excess iron can contribute to tumour
initiation and tumour growth.
• Epidemiological evidence links increased body iron stores to increased cancer
risk. High intake of dietary iron is associated with an increased risk for some
cancers, particularly colorectal cancer. Hereditary haemochromatosis, a genetic
disease that leads to excess iron accumulation, is associated with increased
cancer risk.
• Many types of cancer cells reprogramme iron metabolism in ways that result in
net iron influx. They upregulate proteins that are involved in iron uptake, such
as transferrin receptor 1 (TFR1), STEAP proteins and lipocalin 2 (LCN2), and
decrease the expression of iron efflux proteins, such as ferroportin. Other iron-
regulatory proteins, such as IRP1 and IRP2, contribute to cancer in ways that are
less well understood.
• Iron is crucial to many fundamental cellular processes, including DNA
synthesis, proliferation, cell cycle regulation and the function of proteins
containing iron–sulphur clusters. Iron–sulphur cluster-containing proteins
include enzymes that contribute to maintaining genomic stability, as well as
respiratory function.
• Iron regulates crucial signalling pathways in tumours, including the hypoxia-
inducible factor (HIF) and WNT pathways.
• Measuring the expression of genes encoding proteins involved in iron
metabolism may be useful in cancer prognosis. The expression of ferroportin,
hepcidin, TFR1, haemochromatosis (HFE) and other genes involved in iron
metabolism is linked to the prognosis of patients with breast cancer.
• Iron is a target for cancer therapy. Iron chelators, TFR1 antibodies and cytotoxic
ligands conjugated to transferrin (TF) represent some ways in which iron is
being exploited therapeutically.
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Figure 1. Key features of systemic iron homeostasis in humans
Dietary iron (predominantly in the form of ferric iron (Fe3+)) is absorbed in the duodenum
through the concerted action of a reductase, such as duodenal cytochrome b (DCYTB),
which produces ferrous iron (Fe2+), and divalent metal transporter 1 (DMT1). Iron exits the
basolateral surface of the enterocyte through the iron efflux pump ferroportin, which
functions together with the oxidase hephaestin to oxidize ferrous iron to form ferric iron,
which is loaded onto transferrin (TF). The diferric iron transferrin complex (TF–[Fe3+]2)
circulates through the bloodstream to deliver iron to sites of utilization. Principal among
these sites is the bone marrow, where iron is used in the synthesis of haemoglobin and red
blood cells (RBCs). RBCs circulate for approximately 90 days before they are catabolized
by macrophages of the reticuloendothelial (RE) system. Iron is released from catabolized
haem and effluxed out of the macrophage through the action of ferroportin, where it is
loaded onto TF in the bloodstream, in a process termed iron recycling. TF–[Fe3+]2 is also
delivered to peripheral tissues and the liver, which is the primary organ for the storage of
excess iron. Although small amounts of iron are lost through desquamation, there is no
excretory pathway for iron, so levels of iron in the body are primarily regulated at the
absorption step. Excess iron induces the synthesis of the peptide hormone hepcidin (HP),
which serves as a master regulator of systemic iron homeostasis. HP binds to ferroportin and
triggers its degradation, inhibiting both delivery of dietary iron through the enterocyte and
iron recycling through the macrophage. HP is also induced in response to inflammatory
cytokines and thus contributes to the anaemia of cancer.
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Figure 2. Key steps in mammalian cellular iron metabolism
Iron circulates throughout the body bound to transferrin (TF), which can bind two atoms of
ferric iron (Fe3+). TF-bound iron binds to transferrin receptor 1 (TFR1) on the plasma
membrane of most cells, and the TF– [Fe3+]2–TFR1 complex is endocytosed. In the acidic
environment of the endosome, ferric iron is released from TF and is reduced to ferrous iron
(Fe2+) through the ferrireductase activity of STEAP3. The apotransferrin–TFR1 complex
then recycles back to the cell surface, where apotransferrin participates in further rounds of
iron uptake. In the meantime, ferrous iron is transported out of the endosome into the cytosol
by divalent metal transporter 1 (DMT1), and enters the metabolically active pool of iron (the
labile iron pool). Iron then traffics to multiple destinations. It is inserted into cytosolic
enzymes that are required for DNA synthesis, such as ribonucleotide reductase, and is also
used in haem synthesis and the biogenesis of iron–sulphur clusters, processes that occur
partly in the mitochondria and partly in the cytosol. Excess iron is stored in ferritin, an iron
storage protein. Iron leaves the cell through the activity of ferroportin, an iron efflux pump,
and an oxidase such as ceruloplasmin or hephaestin, which can re-oxidize iron to ferric iron
to enable the loading onto TF.
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Figure 3. Iron uptake and efflux in malignant and non-malignant cells
a | Normal epithelial cells express low levels of transferrin (TF) receptor 1 (TFR1) and
hepcidin and high levels of ferroportin, which collectively lead to a small pool of labile iron.
In breast cells, lipocalin 2 (LCN2), in a complex with a siderophore (SD), may further
reduce levels of intracellular iron by capturing and effluxing SD-bound iron from these
cells, although this is currently hypothetical. b | Cancer cells show increased expression of
TFR1 and hepcidin and low levels of ferroportin, which lead to an increased labile iron pool.
In breast cancer cells, LCN2, in a complex with SD-bound iron, may serve as a further
source of iron. LCN2R, LCN2 receptor.
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Figure 4. Control of cellular iron metabolism by the IRE–IRP regulatory axis
Iron-regulatory protein 1 (IRP1) and IRP2 are crucial proteins in the maintenance of cellular
iron homeostasis. These proteins bind to iron-response elements (IREs) present in either the
5′ or the 3′ untranslated region (UTR) of mRNAs. IREs are found in the 5′ UTR of
mRNAs encoding the ferritin heavy chain (FTH) and ferritin light chain (FTL) subunits,
ferroportin and hypoxia-inducible factor 2α (HIF2α), and in the 3′ UTR of mRNAs
encoding transferrin receptor 1 (TFR1) and IRE-containing isoforms of divalent metal
transporter 1 (DMT1). Binding of IRPs to 5′ IREs inhibits translation, whereas binding to
3′ IREs stabilizes mRNA. IRPs bind to IREs under conditions of low iron levels; under
conditions of high iron levels, IRP1 loses its IRE-binding activity and acquires enzymatic
activity as a cytosolic aconitase, whereas IRP2 is degraded. Thus, under conditions of low
iron levels, the IRE–IRP system functions to increase iron uptake (by stabilizing mRNAs
that encode TFR1 and presumably IRE-containing isoforms of DMT1) and decreases iron
storage and efflux (by inhibiting the translation of ferritin and ferroportin). Binding of IRPs
to mRNAs encoding HIF2α may function as a feedback loop to inhibit erythropoiesis when
iron levels are low171.
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Figure 5. Links between iron, DNA metabolism and genomic integrity
Iron is essential for the activity of the enzymes involved in DNA synthesis, DNA repair and
epigenetic regulation. A di-iron site is essential for the catalytic activity of both constitutive
and p53-inducible ribonucleotide reductase, the enzyme that catalyses the reductive
conversion of ribonucleotides (NDPs) to deoxyribonucleotides (dNDPs) for DNA synthesis.
MMS19 serves as a scaffold for the insertion of iron–sulphur clusters (ISCs) into DNA
repair enzymes such as Xeroderma pigmentosum group D-complementing protein (XPD),
Fanconi anaemia group J protein (FANCJ), DNA replication helicase 2 homologue (DNA2)
and regulator of telomere elongation helicase 1 (RTEL1). The ferrous iron- and 2-
oxoglutarate-dependent enzyme TET1 catalyses the hydroxylation of methylcytosines
(meCs) in the DNA and may have a role in epigenetic control. RRM, ribonucleoside-
diphosphate reductase subunit M.
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Figure 6. A role for iron in canonical WNT signalling
a | In the absence of a trigger for WNT signalling, β-catenin associates with axin,
adenomatous polyposis coli (APC), casein kinase 1 (CK1) and glycogen synthase kinase 3β
(GSK3β) (collectively known as the destruction complex) and is targeted for degradation
(shown by dashed outline). Simultaneously, β-catenin is sequestered from the destruction
complex and associates with E-cadherin. b | In cells with constitutive canonical WNT
signalling (such as cells with mutant APC), β-catenin evades destruction, enters the nucleus
and promotes T cell factor (TCF)–lymphoid enhancer factor (LEF)-dependent transcription
of downstream target genes such as MYC. Iron promotes TCF–LEF-dependent transcription
in cells with such constitutive WNT signalling, resulting in the induction of MYC
expression. MYC in turn transcriptionally induces transferrin receptor 1 (TFR1) and divalent
metal transporter 1 (DMT1) to promote iron uptake. Iron also decreases E-cadherin mRNA
and protein levels in an APC-independent manner. c | Iron chelators decrease TCF–LEF
signalling in cells with constitutive WNT signalling at a step distal to β-catenin by an
unknown mechanism. DVL, disheveled homologue; FZD, frizzled homologue; LRP, low-
density lipoprotein receptor-related protein.
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Table 1
Some cancers in which iron has been implicated
Type of cancer Type of evidence Refs
Non-small-cell lung cancer Cell culture, animal models and epidemiological 5,12,54,79,80,166,172,173
Breast cancer Cell culture, animal models, human tissue
studies and epidemiological
7,8,20,27,43,47,48,69–71,
126,138,165
Renal cell carcinoma Cell culture and animal models 55,139,141–145,174
Hepatocellular cancer Cell culture, animal models and epidemiological 7,22,24–26,36,94,175–177
Oesophageal, stomach, aerodigestive
and gastric cancer
Human tissue studies, animal models and
epidemiological
17,26,178,179
Colorectal cancer Cell culture, human tissue studies, animal
models and epidemiological
7,12,27,45,46,50,95,107,
134–137,180
Prostate cancer Cell culture and epidemiological 19,128
Haematological cancers (leukaemias,
lymphomas and myeloma)
Cell culture, animal models, epidemiological
and clinical case study
75,76,137,148,154,181
Melanoma Cell culture and animal model 151
Pancreatic cancer Cell culture, animal models and clinical trial 37,111
Bladder cancer Cell culture 182
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Table 2
Examples of iron chelators undergoing evaluation as anticancer agents
Chelator name Chelator properties Type of study Refs*
Ciclopirox Fungicide Preclinical and clinical 137,167,181,183
Tachpyridine Ferrous iron chelator Preclinical 172,182,184,185
Dp44mT Di-pyridylketone thiosemicarbazone Preclinical 151
DpC Di-pyridylketone thiosemicarbazone analogue Preclinical 186
BpT 2-benzoylpyridine thiosemicarbazone Preclinical 187
TSC24 Thiosemicarbazone Preclinical 175
Deferasirox Orally available iron chelator used in the
treatment of iron overload
Preclinical and single
patient case report
173,188
Triapine 3-aminopyridine-2-carboxaldehyde
thiosemicarbazone
Preclinical and clinical 189–192,
NCT00941070
Desferoxamine (DFO) Iron chelator used in the treatment of iron
overload
Preclinical and clinical 149
*
For clinical trial identification number NCT00941070 see the ClinicalTrials.gov website.
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